A recent market analysis report has unveiled a promising trajectory for the global moderate-to-severe acne treatments market, highlighting an impressive growth outlook. Valued at USD 1.3 billion in 2023, the market is expected to surge to an estimated USD 2.4 billion by 2033, reflecting a robust compound annual growth rate (CAGR) of approximately 6.2%.
The report underscores the continued advancement and efficacy of retinoid therapy, which remains a dominant force in the acne treatment landscape. In 2022, retinoid therapy commanded a substantial value share of 25.6% and is projected to sustain its leading position throughout the forecast period. This enduring dominance is attributed to ongoing innovations in formulation that enhance the effectiveness of this treatment modality.
Explore The Path To Success And Prosperity With Our Sample Report – Get Your Copy Now
The escalation in market size can be attributed to the escalating prevalence of acne across global populations and the growing urgency to address this dermatological condition effectively. Acne transcends mere physical appearance concerns; it poses a substantial psychological burden and profoundly impacts individuals’ self-esteem and quality of life, particularly in moderate-to-severe cases.
“Our findings underscore the critical need for innovative and efficacious treatments for moderate-to-severe acne,” remarked FMI. “As acne continues to exert a significant toll on individuals’ well-being, there is a pressing demand for therapeutic solutions that not only address the physical symptoms but also alleviate the psychological distress associated with the condition.”
The report serves as a comprehensive guide for stakeholders in the moderate-to-severe acne treatment market, offering insights into key trends, market dynamics, and growth opportunities.
Key Takeaways from Market Study:
- By treatment, retinoid therapy accounts for USD 318.9 Million in 2022 owed to the benefits provided which includes novel formulations, combination therapies, and improved delivery systems, providing patients and healthcare professionals with a wider range of options.
- By route of administration, topical accounts for more than 45% in 2022 globally. Topical acne treatments are available both over-the-counter (OTC) and by prescription. While milder acne may be managed with OTC options, moderate-to-severe acne often requires prescription-strength topical treatments.
- Hospitals holds about 9% of the global market share in 2022. Hospitals may conduct clinical trials and research studies related to acne treatment, including moderate-to-severe cases. These studies contribute to the development of new therapies and advancements in the field of acne treatment, helping to shape the market landscape.
- By region, North America held dominant share in world in 2022. North America has a strong emphasis on aesthetic dermatology, including the management of acne and acne scarring. There is a demand for treatments that not only address acne but also improve the appearance and texture of the skin. This drives the availability of cosmetic procedures and innovative technologies for acne treatment.
Market Competition:
The leading companies are increasing their research & development investments in an effort to create innovative and inventive care with enhanced effectiveness, and affordability. With key focus on expanding their products, companies are strengthening their sales channels in emerging countries.
- In January 2023, the manufacturing plant owned by Abzena in Sanford, North Carolina, was announced to be purchased by Pfizer, according to an agreement the two firms announced.
- In May 2023, Roche’s India division purchased more than 200,000 square feet of office space with Brookfield Properties in the company’s commercial project in Pune’s Baner area.
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on the moderate-to-severe acne treatment market in its latest study, presenting a historical demand assessment of 2017 – 2022 and projections for 2023 – 2033. The global moderate-to-severe acne treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader
The analysis is based on treatment (antibiotics, retinoid therapy, hormonal drugs, anti-inflammatory drugs, chemical peels, laser devices and radiofrequency devices), route of administration (oral, topical and Injectables), and distribution channel (hospitals, clinics, pharmacies & drug stores, e-Commerce and others), across seven key regions around the world.
Drive Your Business Success with A Comprehensive Full Report
Key Companies Profiled:
- Johnson & Johnson
- Bayer AG
- Galderma
- Allergan
- Roche
- Valeant Pharmaceuticals
- Stiefel Laboratories
- Pfizer
- Foamix Pharmaceuticals
- La Roche-Posay
- Proactiv
- Cipla Limited
- GlaxoSmithKline Inc.
- Janssen Pharmaceuticals Inc.
- Sanofi
Key Market Segments Covered in the Moderate-to-Severe Acne Treatment Industry Research:
By Treatment:
- Antibiotics
- Retinoid Therapy
- Hormonal Drugs
- Anti-Inflammatory Drugs
- Chemical Peels
- Laser Devices
- Radiofrequency devices
By Route of Administration:
- Oral
- Topical
- Injectables
By Distribution Channel:
- Hospitals
- Clinics
- Pharmacies & Drug Stores
- e-Commerce
- Others
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
